Literature DB >> 14579153

Coxsackieviral replication and pathogenicity: lessons from gene modified animal models.

Rainer Wessely1.   

Abstract

Coxsackieviruses have been implicated in the pathogenesis of human myocarditis and some forms of dilated cardiomyopathy. A considerable portion of our knowledge about the pathophysiology of viral heart disease is derived from animal studies. In particular, investigations utilising gene-targeted mice provide valuable new insights into various aspects of viral pathogenicity and host factors involved in the control of viral replication. This review focuses on models in cell culture and transgenic animals mimicking coxsackieviral persistence, demonstrating that remarkably low persisting levels of replication-restricted coxsackieviral genomes are associated with an induction of a cytopathic effect in cardiac myocytes, leading to dilated cardiomyopathy in a transgenic mouse model. In this particular animal model, a phenotype is revealed which closely resembles the major hallmarks of human dilated cardiomyopathy. The impact of the innate immune system on coxsackieviral replication is demonstrated by studies in gene-targeted mice deficient of either type I or type II interferon signalling, which have indicated that type I but not type II interferons are essential for the control of early viral replication and survival of coxsackieviral infection.

Entities:  

Mesh:

Year:  2003        PMID: 14579153     DOI: 10.1007/s00430-003-0203-0

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  28 in total

Review 1.  The group B coxsackieviruses and myocarditis.

Authors:  K S Kim; G Hufnagel; N M Chapman; S Tracy
Journal:  Rev Med Virol       Date:  2001 Nov-Dec       Impact factor: 6.989

Review 2.  Viral myocarditis. A review.

Authors:  J F Woodruff
Journal:  Am J Pathol       Date:  1980-11       Impact factor: 4.307

3.  Apoptosis in coxsackievirus B3-caused diseases: interaction between the capsid protein VP2 and the proapoptotic protein siva.

Authors:  A Henke; H Launhardt; K Klement; A Stelzner; R Zell; T Munder
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

4.  Low-level expression of a mutant coxsackieviral cDNA induces a myocytopathic effect in culture: an approach to the study of enteroviral persistence in cardiac myocytes.

Authors:  R Wessely; A Henke; R Zell; R Kandolf; K U Knowlton
Journal:  Circulation       Date:  1998-08-04       Impact factor: 29.690

5.  The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis.

Authors:  A Henke; S Huber; A Stelzner; J L Whitton
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  Protection from lethal coxsackievirus-induced pancreatitis by expression of gamma interferon.

Authors:  M S Horwitz; T Krahl; C Fine; J Lee; N Sarvetnick
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

7.  Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice.

Authors:  J J Hunter; N Tanaka; H A Rockman; J Ross; K R Chien
Journal:  J Biol Chem       Date:  1995-09-29       Impact factor: 5.157

8.  Synergistic interaction of interferon-beta and interferon-gamma in coxsackievirus B3-infected carrier cultures of human myocardial fibroblasts.

Authors:  A Heim; A Canu; P Kirschner; T Simon; G Mall; P H Hofschneider; R Kandolf
Journal:  J Infect Dis       Date:  1992-11       Impact factor: 5.226

9.  Subclassification of dilated cardiomyopathy and interferon treatment.

Authors:  M Stille-Siegener; A Heim; H R Figulla
Journal:  Eur Heart J       Date:  1995-12       Impact factor: 29.983

10.  Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation.

Authors:  K Klingel; C Hohenadl; A Canu; M Albrecht; M Seemann; G Mall; R Kandolf
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.